Ekso Bionics Holdings, Inc. (EKSO)
| Market Cap | 39.84M |
| Revenue (ttm) | 12.80M |
| Net Income (ttm) | -11.92M |
| Shares Out | 3.56M |
| EPS (ttm) | -4.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,582 |
| Open | 11.50 |
| Previous Close | 11.37 |
| Day's Range | 10.85 - 11.64 |
| 52-Week Range | 2.73 - 13.50 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 9.50 (-15.03%) |
| Earnings Date | May 12, 2026 |
About EKSO
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It also develops Ekso Nomad, a power Knee Ankle Foot Orthosis or KAFO; and MediTouch BalanceTutor rehabilitation system, a multidirectional perturbation t... [Read more]
Financial Performance
In 2025, Ekso Bionics Holdings's revenue was $12.80 million, a decrease of -28.60% compared to the previous year's $17.93 million. Losses were -$11.92 million, 5.22% more than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EKSO stock is "Buy." The 12-month stock price target is $9.5, which is a decrease of -15.03% from the latest price.
News
Ekso Bionics Prices $5.852 million Private Placement
SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced th...
Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale
DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artific...
Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch's Groundbreaking BalanceTutor™ Rehabilitation System
SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for ...
Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced th...
Ekso Bionics Reports Third Quarter 2025 Financial Results
SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industr...
Ekso Bionics Holdings Earnings Call Transcript: Q2 2025
Q2 2025 revenue dropped sharply due to delayed enterprise sales, but personal health product revenue grew over 50% year-over-year. Management expects deferred sales to close in 2025 and anticipates personal health to contribute 25% of revenue this year.
Ekso Bionics Reports Second Quarter 2025 Financial Results
SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industr...
Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow
SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today ann...
Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country
SAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industr...
Ekso Bionics' Acceptance into NVIDIA Connect Program Bears Early Fruit
AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company an...
Ekso Bionics Announces New Effective Date of Reverse Stock Split
SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced tha...
Ekso Bionics Announces Reverse Stock Split
SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced tha...
Ekso Bionics Accepted into NVIDIA Connect Program
Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation
Ekso Bionics Holdings Earnings Call Transcript: Q1 2025
Q1 2025 revenue declined year-over-year due to enterprise health softness, but gross margin improved to 54% and net loss narrowed. Personal health segment growth accelerated, supported by new distribution partnerships and a stronger Medicare pipeline.
Ekso Bionics Reports First Quarter 2025 Financial Results
SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industri...
Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow
SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today an...
Bionic P&O Chosen as First Distributor of Ekso Indego® Personal Within the Orthotics & Prosthetics Industry
SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today an...
Ekso Bionics Holdings Earnings Call Transcript: Q4 2024
Record Q4 revenue and improved margins were driven by operational efficiencies and cost savings. Strategic partnerships and CMS reimbursement for Indego Personal set the stage for growth in 2025, with a strong backlog and expanding market access.
Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results
SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and indust...
Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 – Conference Call to Follow
SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today ann...
NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry
Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States Move expected to br...
Ekso Bionics to Showcase Its Device Technology in ‘AI for Good' Webinar on Tuesday, November 19
SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today ann...
Ekso Bionics to Participate at the 15th Annual Craig-Hallum Alpha Select Conference
SAN RAFAEL, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today ann...
Ekso Bionics Holdings Earnings Call Transcript: Q3 2024
Q3 2024 saw $4.1M in sales and improved margins, with strong international growth offsetting U.S. procurement delays. Initial CMS reimbursement for Ekso Indego Personal marked a milestone, and a $5M public offering strengthened cash reserves.
Ekso Bionics Announces Third Quarter 2024 Financial Results
SAN RAFAEL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today rep...